{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:36:03Z","timestamp":1774424163170,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA61\/062"],"award-info":[{"award-number":["RA61\/062"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Female sexual dysfunction (FSD) is prevalent in women with genitourinary syndrome of menopause (GSM). Vaginal estrogen is effective GSM treatment. This study was primarily aimed to evaluate the effects of vaginal administration of conjugated estrogens tablet on postmenopausal FSD using the Female Sexual Function Index (FSFI). Secondary aims were to evaluate vaginal pH, Vaginal Maturation Value (VMV), Normal Flora Index (NFI) and Most Bothersome Symptoms (MBS) changes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A double-blind trial was conducted in postmenopausal women with FSD (FSFI \u226426.55). Sixty-seven participants were randomized into two arms; vaginally administered conjugated estrogens tablet (0.625\u2009mg, daily for 3\u2009weeks then twice weekly for 9\u2009weeks, <jats:italic>n<\/jats:italic>\u00a0=\u200933), or placebo (<jats:italic>n<\/jats:italic>\u00a0=\u200934).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was no significant improvement of FSFI observed in estrogens arm compared to placebo in each domain and overall index (<jats:italic>p<\/jats:italic>\u00a0=\u20090.182). The estrogens significantly improved vaginal pH and VMV, toward more acidity (<jats:italic>p<\/jats:italic>\u00a0=\u2009&lt;\u20090.001), higher VMV (<jats:italic>p<\/jats:italic>\u00a0=\u2009&lt;\u20090.001) and more superficial cells (<jats:italic>p<\/jats:italic>\u00a0=\u2009&lt;\u20090.001). We observed no significant difference in NFI and MBS between arms (<jats:italic>p<\/jats:italic>\u00a0=\u20090.282, 0.182).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We found no significant changes in FSFI, NFI, and MBS, but significant improvement in vaginal pH and VMV in postmenopausal women with FSD treated with vaginally administered conjugated estrogens tablet. Few side-effects were reported.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Thai Clinical Trial Registry identification number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.in.th\/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=3256\">TCTR20180219001<\/jats:ext-link>, prospectively registered since 2018-02-19 11:33:21.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12905-020-01031-4","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T13:03:17Z","timestamp":1597237397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-8040","authenticated-orcid":false,"given":"Thanapob","family":"Bumphenkiatikul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krasean","family":"Panyakhamlerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanittha","family":"Chatsuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chai","family":"Ariyasriwatana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammarin","family":"Suwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charoen","family":"Taweepolcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimit","family":"Taechakraichana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","volume":"281","author":"EO Laumann","year":"1999","unstructured":"Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537\u201344.","journal-title":"JAMA"},{"key":"1031_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2004.08.003","volume":"65","author":"S Hisasue","year":"2005","unstructured":"Hisasue S, Kumamoto Y, Sato Y, Masumori N, Horita H, Kato R, et al. Prevalence of female sexual dysfunction symptoms and its relationship to quality of life: a Japanese female cohort study. Urology. 2005;65:143\u20138.","journal-title":"Urology"},{"key":"1031_CR3","first-page":"2877","volume":"7","author":"M Jaafarpour","year":"2013","unstructured":"Jaafarpour M, Khani A, Khajavikhan J, Suhrabi Z. Female sexual dysfunction: prevalence and risk factors. J Clin Diagn Res. 2013;7:2877\u201380.","journal-title":"J Clin Diagn Res"},{"key":"1031_CR4","first-page":"625","volume":"91","author":"K Peeyananjarassri","year":"2008","unstructured":"Peeyananjarassri K, Liabsuetrakul T, Soonthornpun K, Choobun T, Manopsilp P. Sexual functioning in postmenopausal women not taking hormone therapy in the gynecological and menopause clinic Songklanagarind hospital measured by female sexual function index questionnaire. J Med Assoc Thail. 2008;91:625\u201332.","journal-title":"J Med Assoc Thail"},{"key":"1031_CR5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/jsm.12379","volume":"11","author":"MZ Sungur","year":"2014","unstructured":"Sungur MZ, Gunduz A. A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med. 2014;11:364\u201373.","journal-title":"J Sex Med"},{"key":"1031_CR6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.fertnstert.2013.08.026","volume":"100","author":"JE Buster","year":"2013","unstructured":"Buster JE. Managing female sexual dysfunction. Fertil Steril. 2013;100:905\u201315.","journal-title":"Fertil Steril"},{"key":"1031_CR7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","volume":"21","author":"DJ Portman","year":"2014","unstructured":"Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's sexual health and the North American Menopause Society. Menopause. 2014;21:1063\u20138.","journal-title":"Menopause"},{"key":"1031_CR8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","volume":"13","author":"DW Sturdee","year":"2010","unstructured":"Sturdee DW, Panay N, International Menopause Society Writing G. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13:509\u201322.","journal-title":"Climacteric"},{"key":"1031_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","volume":"19","author":"RJ Baber","year":"2016","unstructured":"Baber RJ, Panay N, Fenton A, I. M. S. Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19:109\u201350.","journal-title":"Climacteric"},{"key":"1031_CR10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/AOG.0000000000000526","volume":"124","author":"DD Rahn","year":"2014","unstructured":"Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124:1147\u201356.","journal-title":"Obstet Gynecol"},{"key":"1031_CR11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","volume":"20","author":"MLS Gass","year":"2013","unstructured":"Gass MLS. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause. 2013;20:888\u2013902 quiz 3-4.","journal-title":"Menopause"},{"key":"1031_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","volume":"18","author":"RJ Santen","year":"2015","unstructured":"Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18:121\u201334.","journal-title":"Climacteric"},{"key":"1031_CR13","volume-title":"National List of Essential Medicines 2018. In: Health MoP, editor. Nonthaburi","author":"National Drug Committee","year":"2018","unstructured":"National Drug Committee. National List of Essential Medicines 2018. In: Health MoP, editor. Nonthaburi 2018."},{"key":"1031_CR14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0009-9236(98)90154-0","volume":"64","author":"S Chompootaweep","year":"1998","unstructured":"Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. Clin Pharmacol Ther. 1998;64:204\u201310.","journal-title":"Clin Pharmacol Ther"},{"key":"1031_CR15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0010-7824(01)00315-8","volume":"65","author":"S Ziaei","year":"2002","unstructured":"Ziaei S, Rajaei L, Faghihzadeh S, Lamyian M. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route. Contraception. 2002;65:329\u201331.","journal-title":"Contraception"},{"key":"1031_CR16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0010-7824(85)90057-5","volume":"31","author":"AR Souka","year":"1985","unstructured":"Souka AR, Kamel M, Einen MA, Saleh F, Sallam H. Vaginal administration of a combined oral contraceptive containing norethisterone acetate. Contraception. 1985;31:571\u201381.","journal-title":"Contraception"},{"key":"1031_CR17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/13697139909038088","volume":"2","author":"WH Utian","year":"1999","unstructured":"Utian WH. The international menopause society menopause-related terminology definitions. Climacteric. 1999;2:284\u20136.","journal-title":"Climacteric"},{"key":"1031_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12905-015-0270-6","volume":"15","author":"R Tungmunsakulchai","year":"2015","unstructured":"Tungmunsakulchai R, Chaikittisilpa S, Snabboon T, Panyakhamlerd K, Jaisamrarn U, Taechakraichana N. Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women. BMC Womens Health. 2015;15:113.","journal-title":"BMC Womens Health"},{"key":"1031_CR19","volume-title":"Fundamentals of biostatistics","author":"B Rosner","year":"2011","unstructured":"Rosner B. Fundamentals of biostatistics. 7th ed. Boston: Brooks\/Cole, Cengage Learning; 2011.","edition":"7"},{"key":"1031_CR20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","volume":"26","author":"R Rosen","year":"2000","unstructured":"Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191\u2013208.","journal-title":"J Sex Marital Ther"},{"key":"1031_CR21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1471-0528.2004.00329.x","volume":"112","author":"E Ozkinay","year":"2005","unstructured":"Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG. 2005;112:234\u201340.","journal-title":"BJOG"},{"key":"1031_CR22","first-page":"128","volume":"18","author":"E Peterson","year":"1985","unstructured":"Peterson E. Bedeutung der Laktobazillen als Normalflora. Gynakologe. 1985;18:128\u201330.","journal-title":"Gynakologe"},{"key":"1031_CR23","first-page":"52","volume":"19","author":"P Y\u00f6r\u00fck","year":"2006","unstructured":"Y\u00f6r\u00fck P, Uygur M, Erenus M, Eren F. The role of vaginal maturation value assessment in prediction of vaginal pH, serum FSH and E2 levels. Marmara Med J. 2006;19:52\u20137.","journal-title":"Marmara Med J"},{"key":"1031_CR24","first-page":"249","volume":"11","author":"A Meisels","year":"1967","unstructured":"Meisels A. The maturation value. Acta Cytol. 1967;11:249.","journal-title":"Acta Cytol"},{"key":"1031_CR25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1530\/jrf.0.0220563","volume":"22","author":"R Stupnicki","year":"1970","unstructured":"Stupnicki R, Teter J. A dynamic approach to the evaluation of oestrogenic effects on the vaginal epithelium in women. J Reprod Fertil. 1970;22:563\u20137.","journal-title":"J Reprod Fertil"},{"key":"1031_CR26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/13697137.2014.981520","volume":"18","author":"P Tuntiviriyapun","year":"2014","unstructured":"Tuntiviriyapun P, Panyakhamlerd K, Triratanachat S, Chatsuwan T, Chaikittisilpa S, Jaisamrarn U, et al. Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy? Climacteric. 2014;18:246\u201351.","journal-title":"Climacteric"},{"key":"1031_CR27","doi-asserted-by":"crossref","unstructured":"Thomas HN, Thurston RC. A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review. Maturitas. 2016;87:49\u201360.","DOI":"10.1016\/j.maturitas.2016.02.009"},{"key":"1031_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00926230590475206","volume":"31","author":"M Wiegel","year":"2005","unstructured":"Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1\u201320.","journal-title":"J Sex Marital Ther"},{"key":"1031_CR29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","volume":"18","author":"G Constantine","year":"2015","unstructured":"Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18:226\u201332.","journal-title":"Climacteric"},{"key":"1031_CR30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/gme.0b013e318182f84b","volume":"15","author":"B Ettinger","year":"2008","unstructured":"Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause. 2008;15:885\u20139.","journal-title":"Menopause"},{"key":"1031_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/1362180053654466","volume":"11","author":"KH Lee","year":"2005","unstructured":"Lee KH, Lee DJ, Kim SM, Je SH, Kim EK, Han HS, et al. Evaluation of effectiveness and safety of natural plants extract (Estromon\u00ae) on Perimenopausal women for 1 year. J of Korea Society of Menopause. 2005;11:1\u201311.","journal-title":"J of Korea Society of Menopause"},{"key":"1031_CR32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ptr.3597","volume":"26","author":"A Chang","year":"2012","unstructured":"Chang A, Kwak BY, Yi K, Kim JS. The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study. Phytother Res. 2012;26:510\u20136.","journal-title":"Phytother Res"},{"key":"1031_CR33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.1993.10","volume":"53","author":"EM Coutinho","year":"1993","unstructured":"Coutinho EM, de Souza JC, da Silva AR, de Acosta OM, Alvarez F, Brache V, et al. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial. Clin Pharmacol Ther. 1993;53:65\u201375.","journal-title":"Clin Pharmacol Ther"},{"key":"1031_CR34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/clpt.1993.186","volume":"54","author":"EM Coutinho","year":"1993","unstructured":"Coutinho EM, Mascarenhas I, de Acosta OM, Flores JG, Gu ZP, Ladipo OA, et al. Comparative study on the efficacy, acceptability, and side effects of a contraceptive pill administered by the oral and the vaginal route: an international multicenter clinical trial. Clin Pharmacol Ther. 1993;54:540\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"1031_CR35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0010-7824(95)00101-F","volume":"51","author":"EM Coutinho","year":"1995","unstructured":"Coutinho EM, O'Dwyer E, Barbosa IC, Gu ZP, Shaaban MM, Aboul-Oyoon M, et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception. 1995;51:355\u20138.","journal-title":"Contraception"},{"key":"1031_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fertnstert.2004.01.025","volume":"82","author":"NJ Alexander","year":"2004","unstructured":"Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril. 2004;82:1\u201312.","journal-title":"Fertil Steril"},{"key":"1031_CR37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00192-012-2009-3","volume":"24","author":"S Srikrishna","year":"2012","unstructured":"Srikrishna S, Cardozo L. The vagina as a route for drug delivery: a review. Int Urogynecol J. 2012;24:537\u201343.","journal-title":"Int Urogynecol J"},{"key":"1031_CR38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2004.11.034","volume":"103","author":"A Hussain","year":"2005","unstructured":"Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release. 2005;103:301\u201313.","journal-title":"J Control Release"},{"key":"1031_CR39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000293657","volume":"24","author":"H Pschera","year":"1989","unstructured":"Pschera H, Hjerpe A, Carlstrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Investig. 1989;24:204\u20137.","journal-title":"Gynecol Obstet Investig"},{"key":"1031_CR40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0015-0282(16)45439-7","volume":"35","author":"B Villanueva","year":"1981","unstructured":"Villanueva B, Casper RF, Yen SS. Intravaginal administration of progesterone: enhanced absorption after estrogen treatment. Fertil Steril. 1981;35:433\u20137.","journal-title":"Fertil Steril"},{"key":"1031_CR41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bpobgyn.2007.08.010","volume":"22","author":"E Cicinelli","year":"2008","unstructured":"Cicinelli E. Intravaginal oestrogen and progestin administration: advantages and disadvantages. Best Pract Res Clin Obstet Gynaecol. 2008;22:391\u2013405.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"1031_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/GME.0000000000000485","volume":"23","author":"S Caruso","year":"2016","unstructured":"Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016;23(1):47\u201354.","journal-title":"Menopause."},{"issue":"2","key":"1031_CR43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/gme.0b013e318184c440","volume":"16","author":"MJ Gast","year":"2009","unstructured":"Gast MJ, Freedman MA, Vieweg AJ, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause. 2009;16(2):247\u201356.","journal-title":"Menopause."},{"key":"1031_CR44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5487\/TR.2017.33.1.071","volume":"33","author":"SJ Kim","year":"2017","unstructured":"Kim SJ, Jin SW, Lee GH, Kim YA, Jeong HG. Evaluation of estrogenic activity of extract from the herbal mixture Cynanchum wilfordii Hemsley, Phlomis umbrosa Turczaninow, and Angelica gigas Nakai. Toxicol Res. 2017;33:71\u20137.","journal-title":"Toxicol Res"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-020-01031-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01031-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:12:29Z","timestamp":1628723549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-01031-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-01031-4","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 039\/2561). All data was collected after the participants gave written consent. Enrollment was on voluntary basis and all participants could withdraw themselves from the protocol at any time.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}